News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Naobios says its development work and GMP manufacturing of vaccine clinical batches will enable FluGen to prepare its 2022 clinical trials in the US.
Boehringer Ingelheim wants to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Novartis has acquired Arctos Medical, a Swiss gene therapy start-up developing optogenetic therapies for treating blindness.
Byooviz is the first ophthalmology biosimilar to gain approval by the US Food and Drug Administration (FDA).